Semaglutide and Vascular Regeneration
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT05870462
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose basic science
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05870462
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Unknown status
Technical summary
Registry record NCT05870462. Randomized; no masking; primary purpose basic science. Start 2023-04-29 (actual); primary completion 2024-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semaglutide and Vascular Regeneration
- Acronym
- SEMA-VR
- Condition
- Atherosclerosis
- Condition
- Cardiovascular Diseases
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Obesity
- Intervention (Drug)
- Semaglutide Pen Injector
- Lead sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
- Collaborator
- Unity Health Toronto
- Collaborator
- Western University, Canada
Record details
- Record id
cardio:ct-nct05870462- Content hash
0f80ea7bf9b29248236fcad995f1ef6351de12a2fcfd3d15e07395f11e13c8b5